Dr. Hamilton on Research Needed in HER2-Positive Breast Cancer

Erika P. Hamilton, MD
Published: Wednesday, Oct 05, 2016


Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

In the neoadjuvant setting, researchers need to best determine which patients with HER2-positive disease will respond to novel compounds, such as T-DM1. For example, results of the phase IIII KRISTINE trial demonstrated that there was a lower pathological complete response (pCR) rate in patients who were treated with trastuzumab emtansine (T-DM1) in combination with pertuzumab (Perjeta) versus docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P). Hamilton hypothesizes that these findings were due to some patients not being truly dependent on the HER2 pathway; therefore, they benefited less from T-DM1.

More research needs to be conducted to predict response to specific agents, and in what sequence they should be administered, she adds.

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

In the neoadjuvant setting, researchers need to best determine which patients with HER2-positive disease will respond to novel compounds, such as T-DM1. For example, results of the phase IIII KRISTINE trial demonstrated that there was a lower pathological complete response (pCR) rate in patients who were treated with trastuzumab emtansine (T-DM1) in combination with pertuzumab (Perjeta) versus docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCH+P). Hamilton hypothesizes that these findings were due to some patients not being truly dependent on the HER2 pathway; therefore, they benefited less from T-DM1.

More research needs to be conducted to predict response to specific agents, and in what sequence they should be administered, she adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x